ING Group’s Zevra Therapeutics ZVRA Stock Holding History

ING Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,719	Closed	-$1.1M	–	865
2018 Q1	$1.1M	Buy	+8,719	New	+$843K	0.02%	314

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ING Group's ZVRA Position: Q2 2018 in Review

ING Group sold out of Zevra Therapeutics (ZVRA) in Q2 2018, closing a stake of 8,719 shares — an estimated $1.1M sold.

ING Group first reported a position in ZVRA in Q1 2018 and held it in 1 quarter. The position peaked at $1.1M in Q1 2018. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2018.

ING Group reported no remaining Zevra Therapeutics position as of Q2 2018 after selling out during the quarter.
ING Group sold 8,719 Zevra Therapeutics shares in Q2 2018, an estimated $1.1M.
ING Group first reported a position in Zevra Therapeutics in Q1 2018 and held it in 1 quarter.
ING Group's Zevra Therapeutics position peaked at $1.1M in Q1 2018.
40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2018.

Based on ING Group's 13F filing for Q2 2018, filed 10 Aug 2018.